Key result
ARBs show promising benefit for hypertension, stroke, and cognitive decline in elderly patients.
Why the study?
Elderly patients with hypertension are often difficult to manage despite the high value of treatment in this population with additional risk factors or cardiovascular disease.
Answers are grounded in this paper and cite their sources.
ARBs may support further evaluation in elderly hypertension; leaves open confirmation of stroke and cognitive benefits in randomized trials.
The world faces the challenge of an ageing population, and for developed countries, the particular challenge is the increasing number of very old people, over 80 years of age. Hypertension is a condition associated with increasing age, but elderly patients with hypertension are often difficult to manage. Nevertheless, treatment of hypertension is of greatest value in older patients who often have additional risk factors or cardiovascular disease. Older patients have generally tolerated antihypertensive therapy well in randomised, placebo-controlled trials. The tolerability of angiotensin receptor blockers (ARBs) is better than that of many other classes of drugs currently used for the management of hypertension and these drugs have virtually no contraindications. Thus, ARBs have a bright future in the management of hypertension and in the treatment of stroke and cognitive decline in the elderly.
No takes yet. Share an insight, caveat, or question.
Gordon T. McInnes (2003) conducted a review in Hypertension in the elderly. Angiotensin receptor blockers (ARBs) was evaluated. Angiotensin receptor blockers (ARBs) are well-tolerated and have a promising role in managing hypertension, stroke, and cognitive decline in elderly patients.
Synapse has enriched 10 related papers. Consider them for comparative context: